hUC-MSC-Exos Nasal Spray: The total therapeutic dosage is set at 400 billion hUC-MSC-EXOs particles. Each nasal administration delivers 40 billion particles, with a total of 10 administrations completing the full course. The treatment is administered on an alternate-day schedule.
Study summary
This clinical study aims to evaluate whether a nasal spray containing exosomes derived from human umbilical cord mesenchymal stem cells (hUC-MSC-EXOs) can safely and effectively improve core symptoms in children aged 3-7 years with autism spectrum disorder (ASD). It is a 24-week, non-randomized, controlled, open-label trial. Sixty pediatric patients with ASD will be non-randomly assigned at a 1:2 ratio to two groups: a no-intervention control group and an active exosome nasal spray treatment group. The treatment group will receive the nasal spray on Mondays, Wednesdays, and Fridays, totaling 10 administrations throughout the study. The no-intervention control group will receive no experimental treatment but will undergo the same assessments and safety checks with the treatment group. This design aims to monitor the safety and efficacy of the hUC-MSC-EXOs nasal spray.
Eligibility
Sex
ALL
Min age
3 Years
Max age
7 Years
Healthy volunteers
No
Inclusion Criteria:
* Diagnosis meets the ICD-11 ASD criteria or DSM-5 ASD clinical diagnostic standards.
* No significant improvement in core symptoms was observed after ≥3 months of standardized behavioral intervention.
* Score ≥30 on the CARS2, indicating mild-to-moderate or more severe autism.
* Aged 3 (inclusive) to 7 (inclusive) years, regardless of gender
* Voluntary participation in this clinical study, with written informed consent provided by the patient's legal guardian, and willingness to undergo examinations, treatment, and cooperate with follow-up visits.
* In the investigator's judgment, the patient is capable of understanding and complying with study requirements.
Exclusion Criteria:
* History of severe allergic reactions.
* Any severe mental disorder or other types of autism spectrum disorders.
* History of epileptic seizures within the past six months.
* Autism secondary to epilepsy, cerebrovascular disease, or traumatic brain injury.
* Disease severity rated as normal, borderline mental disorder, or mild mental disorder on the Clinical Global Impression scale.
* Moderate or severe extrapyramidal symptoms or tardive dyskinesia.
* Severe self-injurious behavior.
* Active systemic or severe localized infections, including human immunodeficiency virus, syphilis, and hepatitis.
* Autoimmune diseases.
* Major organ impairment.
* Severe pulmonary or hematological diseases, malignancies, or immunodeficiency.
* Concurrent treatments that may interfere with the safety and efficacy evaluation of stem cell therapy.
* Participation in other clinical trials within the past three months.
* Other clinical conditions deemed by investigators as unsuitable for study inclusion.
Primary outcome measure(s)
Number of Participants with Treatment-Related Adverse Events — Week 2, Week 6, Week 24 The incidence of treatment-related adverse events will be assessed and graded according to the Common Terminology Criteria for Adverse Events version 5.0. The number of participants experiencing any treatment-related adverse event will be recorded and reported.
Childhood Autism Rating Scale, Second Edition (CARS-2) Score — Week 6, Week 24 Scale Description: The CARS-2 is a 15-item behavior rating scale used to diagnose and assess the severity of ASD.
Range of Scores: 15 to 60. Interpretation: A higher score indicates a worse outcome.
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.